CA-IMPERVA
3.11.2022 13:02:06 CET | Business Wire | Press release
Imperva, Inc., (@Imperva) the cybersecurity leader whose mission is to help organizations protect their data and all paths to it, releases The State of Security Within eCommerce 2022 report, a 12-month analysis by Imperva Threat Research of cybersecurity threats targeting the retail industry. A range of automated threats -- from account takeover, credit card fraud, web scraping, API abuses, Grinch bots, and distributed denial of service (DDoS) attacks -- were a persistent challenge for the eCommerce industry, threatening online sales and customer satisfaction. The continued barrage of attacks on retailers’ websites, applications, and APIs throughout the calendar year, and during the peak holiday shopping season, is a continued business risk for the retail industry.
“The holiday shopping season is a critical period for the retail industry, and security threats could undermine retailers’ bottom line again in 2022,” says Lynn Marks, Senior Product Manager, Imperva. “This industry faces a variety of security risks, the majority of which are automated and operate around the clock. Retailers need a unified approach to stop these persistent attacks, one that focuses on the protection of data and is equipped to mitigate attacks quickly without disrupting shoppers.”
An Automated Adversary: Bad Bots & Online Fraud Plague Retail Sites
In the past 12 months, nearly 40% of traffic on retailers’ websites didn’t come from a human. Instead, it came from a bot, software applications controlled by operators that run automated tasks, often with malicious intent. In the retail industry, the infamous Grinch bot is notorious for inventory hoarding during the holiday shopping season, scooping up high-demand items and making it challenging for consumers to purchase gifts online.
Some of the key trends monitored by Imperva include:
- Of all the traffic on retailers’ websites, nearly one-quarter (23.7%) was attributed specifically to bad bots, malicious automation that contributes to online fraud. The proportion of advanced bots -- scripts that use the latest evasion techniques to mimic human behavior and avoid detection -- on retail sites grew over the prior year (from 23.4% to 31.1%). Advanced bots are a considerable challenge for organizations to stop without the right defenses in place.
- In 2021, bot-related attacks on retail sites grew 10% in October and grew another 34% in November, suggesting that bot operators increase their nefarious efforts around peak holiday shopping periods.
- Account takeover (ATO) is another form of online fraud in which cybercriminals attempt to compromise online accounts by using stolen passwords and usernames. In 2021, 64.1% of ATO attacks used an advanced bad bot. Of all login attempts on retail websites, 22.6% were malicious, nearly twice the volume that was recorded on sites across other industries. Attackers used leaked credentials 94.7% of the time in credential stuffing attacks targeting retailers, compared to 69.6% of the time in other industries.
API Abuses and Attacks Multiply, Creating New Challenges for Retailers
APIs are the invisible connective tissue that enable applications to share data and invoke digital services. Analysis by Imperva Threat Research finds that traffic from an API accounts for 41.6% of all traffic to online retailers’ sites and applications. Of that, 12% of traffic directs to endpoints, like a database, where personal data is stored (e.g. credentials, identification numbers, etc.). More concerning, 3 - 5% of API traffic is directed to undocumented or Shadow APIs, endpoints that security teams don’t know exist or no longer protect.
Exposed or vulnerable APIs are a considerable threat for retailers because attackers can use the API as a pathway for exfiltrating customer data and payment information. API abuses are often carried out through automated attacks where a botnet floods the API with unwanted traffic, seeking vulnerable applications and unprotected data. In 2021, API attacks increased by 35% between September and October, and then spiked another 22% in November on top of the previous months’ elevated attack levels. This finding suggests that bad actors scale their efforts around the holiday shopping season as more data is exchanged between the APIs and applications that power eCommerce services.
Beware of Downtime: DDoS Attacks Continue to Threaten Retailers
A distributed denial of service (DDoS) attack is an automated threat that attempts to disrupt critical business operations by flooding the network or application infrastructure with malicious traffic. The attacks are often launched by a botnet, a group of compromised connected devices that are distributed across the Internet and operated by a single party.
Imperva Threat Research finds that DDoS attacks in 2022 are larger and stronger across all industries. The number of incidents recorded that were greater than 100 Gbps doubled, and attacks larger than 500 Gbps/0.5 Tbps increased 287%. What’s more, those targeted by an attack are often attacked again within 24 hours. In fact, 55% of websites hit by an application layer DDoS and 80% hit by a network layer DDoS were attacked multiple times.
A DDoS attack is a nonstop threat for retailers. The downtime caused by a DDoS attack can lead to site disruption, reputational damage, and revenue loss. A DDoS is a critical threat to online retailers that rely on application performance and availability to enable digital storefronts.
Additional Information:
- Download the The State of Security Within e-Commerce 2022 report
- Learn how Imperva products and solutions help retailers protect their applications, APIs, and data from security risks.
- See how bad bots create business disruption across different industries.
- Check out the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Imperva:
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
